A young child having a hearing test.

Gene Therapy Lets Children Born Deaf Hear for the First Time

Children born profoundly deaf have begun to hear for the first time after a single dose of gene therapy, in what doctors describe as a landmark for the field. The treatment, DB-OTO, was approved by the US Food and Drug Administration in April 2026 under the name Otarmeni, becoming the first gene therapy ever approved for congenital hearing loss. In the CHORD trial, 12 children with profound deafness caused by mutations in the OTOF gene received one infusion of the therapy directly into the inner ear. Hearing improved in 11 of the 12 children, nine reached a level that ended their need for a cochlear implant, and three achieved normal hearing sensitivity within six months. A separate international trial led by Mass Eye and Ear and Fudan University, published in Nature in April 2026, treated 42 people aged from under a year to 32 years and found hearing improved in about 90 percent, with benefits lasting up to two and a half years.

What the Evidence Shows

The therapy works by delivering a working copy of the OTOF gene into the inner ear using a harmless virus, restoring production of otoferlin, a protein that inner hair cells need to pass sound signals to the brain. The condition it treats, known as DFNB9, accounts for roughly 2 to 8 percent of hereditary cases of congenital sensorineural hearing loss and affects about 50 babies born each year in the United States. Cochlear implants, the current treatment, bypass the hair cells entirely, so they manage the symptoms without restoring natural hearing. Younger children and those with healthier inner ears responded best, and children treated in both ears scored higher on language and speech tests. About one in ten participants did not respond, and researchers are following patients to confirm the benefit lasts for life. Reporting and analysis from sources such as The Lancet track the same developments, and specialists following gene therapy for inherited deafness say the direction is now consistent across independent lines of evidence.

The Wider Context

Equity runs through every discussion of gene therapy for inherited deafness. Interventions that require apps, fees or free weekday afternoons reliably reach the people who need them least, so the programmes earning praise are those designed around clinics, workplaces and community venues that already serve everyone. Evaluation reports now publish uptake by income and region as a matter of routine.

What Happens Next

The practical takeaway on gene therapy for inherited deafness is deliberately unglamorous: it works best as part of ordinary, well-delivered care rather than as a standalone fix. Health services are planning on that basis, building the referral routes and follow-up that turn a promising result into population benefit. The gains arrive slowly and then, in the statistics, unmistakably. You can follow related developments in our coverage of health.

It is also worth remembering how quickly the picture in this area has changed before. Positions that looked settled a few years ago have been revised as new data arrived, and the same humility is appropriate now. The strongest coverage of this subject, and the most useful advice, tends to come from sources that update their views openly when the facts move, rather than defending an earlier position long after it has stopped fitting the evidence available.

Leave a Comment

Your email address will not be published. Required fields are marked *